Understanding why patients respond – or fail to respond – to targeted therapies demands more than single analyte analysis. Drug development teams increasingly need spatial, multiomic insight to map immune interactions, quantify cellular activity, and uncover the biological drivers of treatment outcomes. Traditional methods often lack the ability to resolve the diverse molecular and cellular states that shape tissue complexity.
To truly characterize the tissue microenvironment, researchers require tools that can simultaneously detect RNA, proteins, and protein–protein interactions within their native spatial context.
This new scientific poster demonstrates how the RNAscope™ Multiomic LS Assay enables high resolution co detection of PD 1/PD L1 interaction, immune phenotyping markers, and cytokine/effector mRNAs in a single FFPE section from anti PD L1–treated bladder cancer patients.
The results reveal spatially driven immune shifts not captured by interaction analysis alone, highlighting how integrated spatial multiomics can strengthen biomarker discovery, patient stratification, and therapeutic response research.
